Patents by Inventor Hong-Ping Guan

Hong-Ping Guan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Spirolactone compounds
    Patent number: 12102633
    Abstract: Provided herein are spirolactone compounds of Formula I that are useful as inhibitors of ACC1 and/or ACC2. The spirolactone compounds described herein can be used for treating a disease or disorder associated with aberrant ACC1 and/or ACC2 activities, for example, non-alcoholic steatohepatitis (NASH), acne, obesity, diabetes, and cancer. Also provided herein are pharmaceutical compositions comprising the spirolactone compound of Formula I, or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 3, 2023
    Date of Patent: October 1, 2024
    Assignee: Quixgen, Inc.
    Inventors: Yusheng Xiong, Hong-Ping Guan, Wenjun Huang
  • Spirolactone Compounds
    Publication number: 20230355609
    Abstract: Provided herein are spirolactone compounds of Formula I that are useful as inhibitors of ACC1 and/or ACC2. The spirolactone compounds described herein can be used for treating a disease or disorder associated with aberrant ACC1 and/or ACC2 activities, for example, non-alcoholic steatohepatitis (NASH), acne, obesity, diabetes, and cancer. Also provided herein are pharmaceutical compositions comprising the spirolactone compound of Formula I, or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 3, 2023
    Publication date: November 9, 2023
    Applicant: Quixgen, Inc.
    Inventors: Yusheng Xiong, Hong-Ping Guan, Wenjun Huang
  • Spirolactone compounds
    Patent number: 11541046
    Abstract: Provided herein are spirolactone compounds of Formula I that are useful as inhibitors of ACC1 and/or ACC2. The spirolactone compounds described herein can be used for treating a disease or disorder associated with aberrant ACC1 and/or ACC2 activities, for example, non-alcoholic steatohepatitis (NASH), acne, obesity, diabetes, and cancer. Also provided herein are pharmaceutical compositions comprising the spirolactone compound of Formula I, or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: January 3, 2023
    Assignee: Quixgen, Inc.
    Inventors: Yusheng Xiong, Hong-Ping Guan, Wenjun Huang
  • Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor
    Patent number: 11077092
    Abstract: Use of a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor for the treatment of diabetes and related conditions is disclosed.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: August 3, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Hong-Ping Guan, Jose M. Castro-Perez, Harry R. Davis, Samuel E. Engel, Douglas G. Johns, Songnian Lin, Stephen F. Previs, Thomas P. Roddy, Liangsu Wang, Sheng-Ping Wang, Yusheng Xiong
  • Novel Spirolactone Compounds
    Publication number: 20210145822
    Abstract: Provided herein are spirolactone compounds of Formula I that are useful as inhibitors of ACC1 and/or ACC2. The spirolactone compounds described herein can be used for treating a disease or disorder associated with aberrant ACC1 and/or ACC2 activities, for example, non-alcoholic steatohepatitis (NASH), acne, obesity, diabetes, and cancer. Also provided herein are pharmaceutical compositions comprising the spirolactone compound of Formula I, or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 29, 2018
    Publication date: May 20, 2021
    Applicant: Quixgen, Inc.
    Inventors: Yusheng Xiong, Hong-Ping Guan, Wenjun Huang
  • METHODS OF TREATING DIABETES BY ADMINISTERING A GLUCAGON RECEPTOR ANTAGONIST IN COMBINATION WITH A CHOLESTEROL ABSORPTION INHIBITOR
    Publication number: 20170216250
    Abstract: Use of a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor for the treatment of diabetes and related conditions is disclosed.
    Type: Application
    Filed: April 11, 2017
    Publication date: August 3, 2017
    Applicant: Merch Sharp & Dohme Corp.
    Inventors: Hong-Ping Guan, Jose M. Castro-Perez, Harry R. Davis, Samuel E. Engel, Douglas G. Johns, Songnian Lin, Stephen F. Previs, Thomas P. Roddy, Liangsu Wang, Sheng-Ping Wang, Yusheng Xiong
  • METHODS OF TREATING DIABETES BY ADMINISTERING A GLUCAGON RECEPTOR ANTAGONIST IN COMBINATION WITH A CHOLESTEROL ABSORPTION INHIBITOR
    Publication number: 20150320724
    Abstract: Use of a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor for the treatment of diabetes and related conditions is disclosed.
    Type: Application
    Filed: December 8, 2013
    Publication date: November 12, 2015
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Hong-Ping Guan, Jose M. Castro-Perez, Harry R. Davis, Samuel E. Engel, Douglas G. Johns, Songnian Lin, Stephen F. Previs, Thomas P. Roddy, Liangsu Wang, Sheng-Ping Wang, Yusheng Xiong